



# UNITED STATES PATENT AND TRADEMARK OFFICE

*clg*  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/866,925	05/30/2001	Richard J. Feldmann	3124-Z	5146

7590 01/24/2007  
Law Office of Jim Zegeer  
801 North Pitt Street, #108  
Alexandria, VA 22314

EXAMINER
----------

BRUSCA, JOHN S

ART UNIT	PAPER NUMBER
----------	--------------

1631

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/24/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

## Office Action Summary

**Application No.**

09/866,925

**Applicant(s)**

FELDMANN, RICHARD J.

**Examiner**

John S. Brusca

**Art Unit**

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 06 December 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 20-37 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 20-37 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 8/31/2006.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_.

Art Unit: 1631

## **DETAILED ACTION**

### ***Reopening of prosecution after Vacatur and Remand by the Board of Appeals and Interferences***

1. On 28 September 2006 the Board of Appeals and Interferences issued a Vacatur and Remand which necessitates reopening of prosecution to present new and modified grounds of rejection. Consequently this Office action is a non-final Office action.
2. In the Vacatur and Remand the Board of Appeals and Interferences (hereinafter referred to as the Board) raised several issues that were suggested for consideration in further prosecution. The Board expressed concern that the rejection for lack of enablement did not take into account the limitations of all rejected claims. The rejection under 35 U.S.C. 112, first paragraph for lack of enablement detailed below has been expanded and revised relative to the rejection in the Examiner's Answer mailed 09 December 2005 to make clear that the grounds of rejection is that the claimed subject matter of all rejected claims is not enabled to be **used** by one of skill in the art. None of the limitations of the rejected claims serve to limit the claimed subject matter to satisfy the enablement requirement of 35 U.S.C 112, first paragraph because all claims are drawn to analysis of connectrons and connectron analysis cannot be used by one of skill in the art as detailed below. The Board stated that the claimed subject matter only appeared to require locating connectrons in sequence data, however the rejection for lack of enablement acknowledges that locating connectrons in sequence data can be performed but that the result of the analysis cannot be used by one of skill in the art.

Art Unit: 1631

3. The Board further expressed concern that proper claim construction analysis was not performed in prior prosecution of this application, and noted several questions that should be addressed. The Board stated that claim 20 does not appear to be limited to connectrons. Upon further review of the specification, the limitations of claim 20 are not identical with the description and definitions of connectrons in the specification, see for example the specification at pages 1-2 which states that a connectron is a tetradic relationship between sequences C1 and T1 (which are identical sequences on DNA and RNA, respectively) and C2 and T2 (which are identical relationships on DNA and RNA, respectively), where the tetrads are formed by a triple stranded complex between adjacent C1 and C2 sequences and non-adjacent T1 and Ts sequences in the RNA and DNA. New grounds of rejection have been applied under 35 U.S.C. 112, second paragraph in an attempt to clarify whether claim 20 is limited to identification of connectrons.

4. The Board suggested that Francois et al. might be prior art under 35 U.S.C. 103(a). However upon review of Francois et al. it is clear that Francois et al. is primarily concerned with the binding of single stranded DNA oligonucleotides to double stranded and single stranded regions of a DNA target oligonucleotide (see figure 1). Francois et al., as noted by the Board, does describe in the second column of page 65 binding of oligonucleotides to noncontiguous regions of RNA, however claim 20 has a limitation that the C1 and C2 sequences of the RNA molecule are adjacent. At this time the Office does not choose to apply Francois et al. as prior art to claim 20 because the noncontiguous RNA sites of Francois et al. are not disclosed sufficiently in Francois et al. to determine if they could reasonably be interpreted to be adjacent and noncontiguous. The applicants are encouraged to amend the claims that are rejected under 35

Art Unit: 1631

U.S.C. 112, second paragraph in such a way that the claims clearly require analysis of connectrons as defined in the instant specification.

5. The Board stated a concern that claims 28-37 begin with the term "Use". The concern has been addressed by the applicant's amendment to claims 28-37 filed 06 December 2006.

***Claim Rejections - 35 USC § 102***

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claim 26 rejected under 35 U.S.C. 102(b) as being anticipated by Fleischmann et al.

The claim is drawn to a method of sequencing a genome, determining transcriptional control regions, and outputting the results.

Fleischmann et al. shows in the abstract and throughout a method of sequencing the genome of Haemophilus influenzae. Fleischmann et al. shows in Table 1 a step of annotation of the genomic sequence that includes regulatory regions. Fleischmann et al. shows on pages 508-509 that the data was deposited in a publicly accessible database facility, the Genome Sequence DataBase.

***Claim Rejections - 35 USC § 112***

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1631

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 20-37 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention.

In *In re Wands* (8 USPQ2d 1400 (CAFC 1988)) the CAFC considered the issue of enablement in molecular biology. The CAFC summarized eight factors to be considered in a determination of "undue experimentation." These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims.

In considering the factors for the instant claims:

a) Quantity of experimentation: The only utility asserted by the specification is to use connectron symmetries to predict control of gene expression (see for example pages 10, 11, 14, and 15 of the specification). In order to practice the claimed invention one of skill in the art must identify and use a connectron to predict regulation of gene expression. In some embodiments changes in connectron behavior that correlate with changes in gene expression is monitored or effected. For the reasons discussed below, there would be an unpredictable amount of experimentation required to practice the claimed invention.

Art Unit: 1631

b) The amount of direction or guidance presented: The claimed invention is a method of identification of sequences that have a connectron relationship and act to modulate gene expression. On page one, the specification defines connectrons as a tetradic structure between two sequences in an RNA transcript of a genomic sequence and two sequences in double stranded genomic DNA. Figure 4 depicts a connectron. The specification speculates without evidence on pages 1-3 that triple-stranded (triplex) structures will form between RNA and double stranded DNA in chromatin where connectron symmetries are identified. The specification does not provide guidance that there are any limitations on formation of triplex structures, and only implies that regions of RNA with identical sequence to one strand of a double stranded DNA sequence will form triplex structures. The specification does not address why all RNA transcripts of genes would not form a continuous triplex structure with the gene from which it is transcribed. The specification provides guidance to identify connectron symmetries in genomic sequences on pages 31-34. The specification does not provide detailed guidance to use identified connectron symmetries because the specification does not show whether or not connectrons as depicted in figure 4 form within cells or have an effect on gene expression. The specification does not provide specific guidance for monitoring or effecting changes in connectron behavior that correlate with gene expression.

c) The presence or absence of working examples: The specification provides working examples of identification of connectron symmetries by computer-mediated searching of genomic sequences in pages 35-188. However, the specification does not provide evidence that connectron symmetries in genomic sequences result in formation of triplex RNA-DNA structures

Art Unit: 1631

or that if connectron triplex structures do exist that connectrons control gene expression. The specification does not provide working examples of using identified connectron symmetries to predict effects on gene expression. The specification does not provide working examples of monitoring or effecting changes in connectron behavior that correlate with gene expression.

d) The nature of the invention: The nature of the invention, gene expression control, is complex.

e) The state of the prior art: One of skill in the art, after reading the specification, would not know that connectron symmetries identified by computer-mediated searches of genomic sequences would allow for prediction of gene expression of genes that have connectron symmetries. The specification does not provide experimental evidence that connectron symmetries cause modulation of gene expression. Neither the prior art nor post-filing art shows connectrons. Mattick (published in 2001, one year after the effective instant filing date) reviews effects of RNA molecules on gene regulation. Mattick does not show connectrons as defined in the instant specification. Chan et al. reviews triplex DNA formation. Chan et al. shows in figures 1A-C that short stretches of oligonucleotides may form parallel or antiparallel triplex structures. Chan et al. shows in figures 1B that parallel triplex forming oligonucleotides form bonds between C and T residues of the oligonucleotide and G and A residues of the double stranded DNA molecule. Figure 1C shows that antiparallel triplex forming oligonucleotides form bonds between A, G, and T residues of the oligonucleotide and A, G, and A residues of the double stranded DNA. Chan et al. characterize the limited range of base pairing possibilities in triplex structures as pyrimidine binding motifs or purine binding motifs. Chan et al. describe on pages



Art Unit: 1631

268-273 the unpredictability and difficulty of forming desired triplex structures that are limited to the purine motif or the pyrimidine motif. Chan et al. does not show a mechanism that allows for triplex structures to form with any and all regions of identity between an RNA transcript and a region of double stranded DNA that has an identical sequence in one of the two strands of DNA, as required for connectron formation as defined in the instant specification.

f) The relative skill of those in the art: The skill of those in the art of gene expression is high.

g) The predictability of the art: The predictability of the relationship of connectron symmetries and gene expression is unknown in the prior art and is not described in the instant specification.

h) The breadth of the claims: The claims are broad in that they are drawn to identification and modulation of connectron symmetries whose relationship to gene expression is not established.

The skilled practitioner would first turn to the instant specification for guidance in using the claimed invention. However, the specification lacks any evidence that connectrons form in cells or that connectron symmetries are related to gene expression. As such, the skilled practitioner would turn to the prior art for such guidance, however the prior art does not discuss connectron symmetries. Chan et al. shows that triplex formation occurs only with oligonucleotides with a purine rich or pyrimidine rich motif, rather than with any identical sequence as suggested in the specification. Finally, said practitioner would turn to trial and error experimentation to determine a relationship between connectron symmetries and gene

Art Unit: 1631

expression. Such amounts to undue experimentation.

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

10. Claims 20-37 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 20 and 28-37 are indefinite for recitation of the term “data” in lines 4, 7, 8, 13, and 14 because it is not clear how sequence data can bind RNA molecules as recited in claim 20. The rejection would be overcome by amending claim 20 to make it clear that the DNA sequence data represents a DNA molecule that can bind to an RNA molecule.

Claim 20 is indefinite because it is not clear if the method requires identification of single stranded DNA sequences or double stranded DNA sequences that bind RNA sequences, i.e., it is not clear if the method identifies connectrons that comprise triple helical regions as defined in the specification.

Claims 20 and 28-37 are indefinite because it is not clear if the C1 and C2 sequences are genomic sequences that are transcribed and appear as adjacent sequences in the RNA molecule.

Claim 20 is indefinite because it is not clear if there is a gap between the T1 and T2 sequences.

Art Unit: 1631

Claims 21-25 and 27 are indefinite because the claims appear to require steps of physical transformations to cells comprising the genomic sequences analyzed by the claimed methods, but the claim states that the methods are computer mediated.

***Response to Arguments***

11. Applicant's arguments filed 06 December 2006 have been fully considered but they are not persuasive. The applicants have filed a number of treatises that deal generally with analysis of DNA sequences. The papers supplied by the applicants do not discuss or address enablement of the methods of analysis of connectrons as defined in the instant specification.

***Conclusion***

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

*John S. Brusca 16 January 2007*

John S. Brusca

Primary Examiner

Art Unit 1631

jsb